Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2025.08.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-plasmid defense in hypervirulent involves Type I-like and Type IV restriction modification systems.
Emerg Microbes Infect
September 2025
Infectious Diseases Translational Research Programme, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Hypervirulent (hvKp) and classical multidrug-resistant (MDR) strains belong to distinct lineages and hvKp are typically characterized by hypermucoid capsules that have been shown to limit horizontal gene transfer (HGT), including plasmid acquisition. However, the convergence of hypervirulence and MDR is increasingly common worldwide. When we profiled 127 antibiotic-susceptible hvKp strains, we found that most (86%) are highly permissive to plasmid transfer despite their capsules.
View Article and Find Full Text PDFO-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene via mA modification.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Urology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Objectives: Bladder cancer is a common malignancy with high incidence and poor prognosis. N-methyladenosine (mA) modification is widely involved in diverse physiological processes, among which the mA recognition protein YTH N-methyladenosine RNA binding protein F2 (YTHDF2) plays a crucial role in bladder cancer progression. This study aims to elucidate the molecular mechanism by which O-linked -acetylglucosamine (O-GlcNAc) modification of YTHDF2 regulates its downstream target, period circadian regulator 1 (), thereby promoting bladder cancer cell proliferation.
View Article and Find Full Text PDFMicrofluidic Microspheres Loaded with Aggregation-Induced Emission Nanomicelles for Theranostic Applications in Osteoarthritis.
Adv Healthc Mater
September 2025
State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, Wuhan, 430070, P. R. China.
Osteoarthritis (OA) is a common degenerative joint disease, and early diagnosis and effective treatment are essential for managing its progression. This study focuses on the development of a novel drug delivery system using aggregation-induced emission (AIE) probe for enhanced fluorescence imaging and targeted therapy in OA. TPE-S-BTD, an AIE probe, is synthesized and characterized for its photophysical properties, demonstrating significant aggregation-induced fluorescence enhancement.
View Article and Find Full Text PDFSuccessful Identification and Treatment of Cancer of Unknown Primary Originating From Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor Therapy: A Case Report.
Cancer Rep (Hoboken)
September 2025
Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.
Background: Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies.
View Article and Find Full Text PDFAdvances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.
Med Sci Monit
August 2025
Independent Laboratory of Translational Medicine, Medical University of Lublin, Lublin, Poland.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality, with high rates of recurrence and chemoresistance. Advances in understanding the molecular biology of EOC, particularly BRCA mutations and homologous recombination deficiency (HRD), have led to more targeted therapies. This review provides an updated summary of systemic treatments for EOC, with an emphasis on personalized therapy approaches and emerging therapeutic strategies.
View Article and Find Full Text PDF